Neil Mody
YOU?
Author Swipe
View article: Accelerating antibody development: sequence and structure-based models for predicting developability properties via size exclusion chromatography
Accelerating antibody development: sequence and structure-based models for predicting developability properties via size exclusion chromatography Open
Experimental screening for biopharmaceutical developability properties typically relies on resource-intensive, and time-consuming assays such as size exclusion chromatography (SEC). This study highlights the potential of in silico models t…
View article: Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning Open
Highly concentrated antibody solutions are necessary for developing subcutaneous injections but often exhibit high viscosities, posing challenges in antibody-drug development, manufacturing, and administration. Previous computational model…
View article: Accelerating Antibody Development: Sequence and Structure-Based Models for Predicting Developability Properties through Size Exclusion Chromatography
Accelerating Antibody Development: Sequence and Structure-Based Models for Predicting Developability Properties through Size Exclusion Chromatography Open
Experimental screening for biopharmaceutical developability properties typically relies on resource-intensive, and time-consuming assays such as size exclusion chromatography (SEC). This study highlights the potential of in silico models t…
View article: 1058 Development of AZD9793 for GPC3<sup>+</sup> solid tumor treatment: a next generation CD8-guided T cell engager with superior therapeutic index versus conventional formats
1058 Development of AZD9793 for GPC3<sup>+</sup> solid tumor treatment: a next generation CD8-guided T cell engager with superior therapeutic index versus conventional formats Open
View article: Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies Open
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the…
View article: Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics Open
Machine learning has been recently used to predict therapeutic antibody aggregation rates and viscosity at high concentrations (150 mg/ml). These works focused on commercially available antibodies, which may have been optimized for stabili…
View article: Critical Reagents for Ligand-Binding Assays: Process Development Methodologies to Enable High-Quality Reagents
Critical Reagents for Ligand-Binding Assays: Process Development Methodologies to Enable High-Quality Reagents Open
Development of biotherapeutics require pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity assays that are frequently in a ligand-binding assay (LBA) format. Conjugated critical reagents for LBAs are generated conjugation of the bio…
View article: Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity
Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity Open
Preferential interactions of excipients with the antibody surface govern their effect on the stability of antibodies in solution. We probed the preferential interactions of proline, arginine.HCl (Arg.HCl), and NaCl with three therapeutical…
View article: Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association
Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association Open
View article: Computational tool for the early screening of monoclonal antibodies for their viscosities
Computational tool for the early screening of monoclonal antibodies for their viscosities Open
Highly concentrated antibody solutions often exhibit high viscosities, which present a number of challenges for antibody-drug development, manufacturing and administration. The antibody sequence is a key determinant for high viscosity of h…